ID27840A - Turunan-turunan asam hidroksi pipekolat hidroksamat sebagai inhibitor-inhibitor mmp - Google Patents

Turunan-turunan asam hidroksi pipekolat hidroksamat sebagai inhibitor-inhibitor mmp

Info

Publication number
ID27840A
ID27840A IDW20010327A ID20010327A ID27840A ID 27840 A ID27840 A ID 27840A ID W20010327 A IDW20010327 A ID W20010327A ID 20010327 A ID20010327 A ID 20010327A ID 27840 A ID27840 A ID 27840A
Authority
ID
Indonesia
Prior art keywords
hydrocsamic
hydrocamats
mmp inhibitors
pipecolate
acid
Prior art date
Application number
IDW20010327A
Other languages
English (en)
Indonesian (id)
Inventor
Kim Francis Mcclure
Mark Carl Noe
Michael Anthony Letavic
Louis Stanley Chupak
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID27840A publication Critical patent/ID27840A/id

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28Halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
IDW20010327A 1998-08-12 1999-08-05 Turunan-turunan asam hidroksi pipekolat hidroksamat sebagai inhibitor-inhibitor mmp ID27840A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9623298P 1998-08-12 1998-08-12

Publications (1)

Publication Number Publication Date
ID27840A true ID27840A (id) 2001-04-26

Family

ID=22256467

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010327A ID27840A (id) 1998-08-12 1999-08-05 Turunan-turunan asam hidroksi pipekolat hidroksamat sebagai inhibitor-inhibitor mmp

Country Status (43)

Country Link
US (2) US6329397B1 (fr)
EP (1) EP1104403B1 (fr)
JP (1) JP2002522528A (fr)
KR (1) KR20010085374A (fr)
CN (1) CN1316995A (fr)
AP (1) AP2001002070A0 (fr)
AR (1) AR019241A1 (fr)
AT (1) ATE325791T1 (fr)
AU (1) AU766366B2 (fr)
BG (1) BG105323A (fr)
BR (1) BR9912909A (fr)
CA (1) CA2340202C (fr)
CZ (1) CZ2001484A3 (fr)
DE (1) DE69931266T2 (fr)
DZ (1) DZ2870A1 (fr)
EA (1) EA200100126A1 (fr)
EE (1) EE200100086A (fr)
ES (1) ES2263279T3 (fr)
GE (1) GEP20033117B (fr)
GT (1) GT199900131A (fr)
HK (1) HK1040242A1 (fr)
HN (1) HN1999000131A (fr)
HR (1) HRP20010098A2 (fr)
HU (1) HUP0103452A3 (fr)
ID (1) ID27840A (fr)
IL (1) IL141030A0 (fr)
IS (1) IS5813A (fr)
MA (1) MA26675A1 (fr)
NO (1) NO20010686L (fr)
NZ (1) NZ509296A (fr)
OA (1) OA11594A (fr)
PA (1) PA8479201A1 (fr)
PE (1) PE20000951A1 (fr)
PL (1) PL346041A1 (fr)
SK (1) SK1872001A3 (fr)
SV (1) SV1999000123A (fr)
TN (1) TNSN99156A1 (fr)
TR (1) TR200100474T2 (fr)
UA (1) UA59453C2 (fr)
UY (1) UY25993A1 (fr)
WO (1) WO2000009485A1 (fr)
YU (1) YU5201A (fr)
ZA (1) ZA200101042B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
WO2000012093A1 (fr) * 1998-08-31 2000-03-09 Merck & Co., Inc. Procede de traitement des maladies neurodegeneratives
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (fr) 1999-08-12 2001-03-07 Pfizer Products Inc. Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite
EP1138680A1 (fr) * 2000-03-29 2001-10-04 Pfizer Products Inc. Acides gem-substitués alpha-sulfonylamino hydroxamiques comme inhibiteurs de métalloprotease
JP2001322977A (ja) * 2000-05-12 2001-11-20 Kotobuki Seiyaku Kk ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
JP2002105073A (ja) * 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
BR0207209A (pt) 2001-02-14 2004-01-27 Warner Lambert Co Inibidores de metaloproteinase de matriz de pirimidina
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
BR0213233A (pt) 2001-10-12 2005-01-04 Warner Lambert Co Alcinos inibidores de metaloproteinase de matriz
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
MXPA04012932A (es) * 2002-06-26 2005-06-03 Japan Bioindustry Ass Nuevo derivado de azasugar y farmaco que lo contiene como ingrediente activo.
CA2489722A1 (fr) * 2002-07-17 2004-01-22 William Howard Roark Combinaison d'un inhibiteur alcyne allosterique de la metalloprotease matricielle-13 et de celecoxib ou de valdecoxib
EP1525030A1 (fr) * 2002-07-17 2005-04-27 Warner-Lambert Company LLC Combinaison d'un inhibiteur alcyne allosterique de metalloproteinase matricielle 13 avec un inhibiteur selectif de cyclooxygenase-2, a l'exception du celecoxib ou du valdecoxib
WO2004014868A2 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de pyrimidine 2,4-diones, utilises comme inhibiteurs de metalloproteinase matricielle
CA2494014A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives monocycliques en tant qu'inhibiteurs de metalloproteinases matricielles
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014923A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloprotease bicycliques condenses avec la pyrimidinone
WO2004014378A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de 3-isoquinolinone utilises comme inhibiteurs de metalloprotease de matrice
WO2004014908A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloproteinases heterobicycliques
WO2004014909A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives fusionnes de la tetrahydropyridine inhibiteurs de la metalloprotease matricielle
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014880A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de chromone inhibiteurs de metalloproteinase de matrice
JP2006504665A (ja) 2002-08-13 2006-02-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのアザイソキノリン誘導体
US20060223884A1 (en) * 2005-03-22 2006-10-05 Nicolas Chapal Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
BRPI0910034B1 (pt) 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
SI2243772T1 (sl) 2009-04-14 2012-05-31 Affectis Pharmaceuticals Ag Novi antagonisti p x r in njihova uporaba
WO2012110190A1 (fr) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Nouveaux antagonistes p2x7r et leur utilisation
WO2012163456A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2012163792A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
DE202016007195U1 (de) 2016-11-16 2017-11-17 Bernhard Kohler Strombegrenzende Schalteinrichtung
WO2020160140A1 (fr) * 2019-01-29 2020-08-06 Darsha Llc Compositions et méthodes pour traiter une maladie pulmonaire avec des inhibiteurs de métalloprotéinase matricielle

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198326T1 (de) * 1995-04-20 2001-01-15 Pfizer Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
AU725831C (en) * 1995-12-08 2002-10-17 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
AU741893B2 (en) * 1996-08-28 2001-12-13 Procter & Gamble Company, The Substituted cyclic amine metalloprotease inhibitors
WO1998033768A1 (fr) * 1997-02-03 1998-08-06 Pfizer Products Inc. Derives d'acide arylsulfonylaminohydroxamique
CA2280151C (fr) * 1997-02-11 2005-12-13 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Also Published As

Publication number Publication date
HK1040242A1 (zh) 2002-05-31
MA26675A1 (fr) 2004-12-20
US6329397B1 (en) 2001-12-11
JP2002522528A (ja) 2002-07-23
IS5813A (is) 2001-01-16
HN1999000131A (es) 2000-03-24
WO2000009485A1 (fr) 2000-02-24
HUP0103452A2 (hu) 2002-04-29
YU5201A (sh) 2003-07-07
UA59453C2 (uk) 2003-09-15
SK1872001A3 (en) 2002-08-06
ATE325791T1 (de) 2006-06-15
CA2340202A1 (fr) 2000-02-24
TNSN99156A1 (fr) 2005-11-10
DE69931266D1 (en) 2006-06-14
EE200100086A (et) 2002-08-15
GEP20033117B (en) 2003-11-25
NO20010686D0 (no) 2001-02-09
KR20010085374A (ko) 2001-09-07
CZ2001484A3 (cs) 2002-05-15
AP2001002070A0 (en) 2001-03-31
TR200100474T2 (tr) 2001-06-21
DZ2870A1 (fr) 2003-12-15
US20030008901A1 (en) 2003-01-09
CA2340202C (fr) 2006-02-07
PA8479201A1 (es) 2000-09-29
EP1104403A1 (fr) 2001-06-06
UY25993A1 (es) 2000-03-31
ZA200101042B (en) 2002-10-07
ES2263279T3 (es) 2006-12-01
OA11594A (en) 2004-07-11
SV1999000123A (es) 2000-07-06
AU4924799A (en) 2000-03-06
HRP20010098A2 (en) 2002-02-28
PL346041A1 (en) 2002-01-14
EP1104403B1 (fr) 2006-05-10
DE69931266T2 (de) 2007-02-15
AR019241A1 (es) 2001-12-26
EA200100126A1 (ru) 2001-08-27
GT199900131A (es) 2001-02-02
HUP0103452A3 (en) 2002-10-28
BR9912909A (pt) 2001-05-08
NO20010686L (no) 2001-04-09
NZ509296A (en) 2003-10-31
IL141030A0 (en) 2002-02-10
AU766366B2 (en) 2003-10-16
CN1316995A (zh) 2001-10-10
PE20000951A1 (es) 2000-09-27
BG105323A (en) 2001-10-31

Similar Documents

Publication Publication Date Title
ID27840A (id) Turunan-turunan asam hidroksi pipekolat hidroksamat sebagai inhibitor-inhibitor mmp
ID24626A (id) Turunan-turunan asam hidroksamat sebagai penghambat metaloprotease matriks (mmp)
ID26222A (id) Hidroksamida asam(4-arilsulfonilamino)-tetrahidropiran-4-karboksilat
ID28833A (id) Turunan asam 3-aril-2-hidroksipropionat
ID22095A (id) Asam aril-akrilat ester
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DE69918278D1 (de) Substituierte indolalkansäure
ID26089A (id) Turunan-turunan asam hidroksamat bisiklik
NO20000877L (no) Forbedret syrekorrosjonsinhibitor
ID20809A (id) Asam diaminokarboksilat tersubstitusi
DK1100769T3 (da) Aminomethylcarboxylsyrederivater
DE69933283D1 (de) Photoaktivierbare nukleinsäure-derivate
ID20807A (id) Asam sulfonilaminokarboksilat
IS5735A (is) Ný 3-arýl-2-hýdroxýprópínsýruafleiða III
DE60008527D1 (de) Zellproliferation inhibitoren
DE60009675D1 (de) Protonenpumpinhibitoren enthaltende zusammensetzung
ID27390A (id) Pembuatan asam akrilat
IS5562A (is) Nýjar díhýdroxýhexanósýru afleiður
NO20014875D0 (no) Promedikamenter for trombin inhibitorer
NO20003814D0 (no) Trombininhibitorer
ID28810A (id) Senyawa-senyawa amida-omega asam n-arilsulfonilamino
NO20003105L (no) Fenylaminoalkylkarboksylsyre-derivater samt medisinske sammensetninger omfattende slike
EE9900180A (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren